Russia plans production of Myrcludex B, a drug against hepatitis Delta

29 July 2019

Russia may become the world’s first country that will have its own production of a drug for the treatment of hepatitis Delta, according to recent statements by Pavel Bogomolov, head of the Department of Hepatology at Moscow Vladimirsky Regional Research Clinical Institute.

According to him and some other Russian pharma sector analysts, preparations for the launch of the drug, which is known as Myrcludex B (bulevirtide), are currently underway, reports The Pharma Letter’s local correspondent.

The results of a trial presented at this year’s International Liver Congress trial suggest that bulevirtide is a promising treatment for chronic HDV infection, and that the combination of bulevirtide and PEG-IFN-α has the potential to cure HBV/HDV coinfection in some patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK